期刊
MOLECULAR THERAPY
卷 16, 期 3, 页码 481-486出版社
CELL PRESS
DOI: 10.1038/sj.mt.6300387
关键词
-
资金
- NIA NIH HHS [R21 AG 21610] Funding Source: Medline
- NINDS NIH HHS [F1 NS 45510] Funding Source: Medline
A unifying characteristic of prion diseases is the conversion of a normal cellular protein (PrPC) to an abnormal pathogenic conformation, designated PrPSC. Antibodies directed against PrPc, when added to scrapie-infected cell cultures or passively administered in vivo, can result in elimination of PrPSC or prevent its replication, respectively. In our efforts to develop an approach with potential prophylactic utility we employed a recombinant adeno-associated vector type 2 (rAAV2) viral vector platform to express PrPC-specific single-chain fragment variable (scFv) antibodies within the central nervous system (CNS) of susceptible mice that were subsequently inoculated peripherally with infectious prions. Vector expressed scFvs delayed onset of prion pathogenesis as evidenced by improvements in clinical signs and rotarod performance, in extended incubation periods, and in decreased PrPSC burden in the CNS. This novel antibody delivery platform enables the in vivo translation of prion prophylactics to other species afflicted by transmissible spongiform encephalopathies (TSEs) and which also has relevance to the development of therapeutics for other protein-misfolding diseases such as Alzheimer's or Parkinson's disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据